Open AccessInhibitory activity of HIV envelope gp120 dominates over its antigenicity for human T cells
Author(s) -
MANCA F.,
WALKER L.,
NEWELL A.,
CELADA F.,
HABESHAW J. A.,
DALGLEISH A. G.
Publication year - 1992
Publication title -
clinical & experimental immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 135
eISSN - 1365-2249
pISSN - 0009-9104
DOI - 10.1111/j.1365-2249.1992.tb03032.x
Subject(s) - antigenicity , polyclonal antibodies , glycoprotein , antigen , epitope , antibody , t cell , biology , viral envelope , microbiology and biotechnology , chemistry , immune system , immunology
SUMMARY HIV‐1 envelope glycoprotein (gp120), as a CD4‐binding reactant, has been shown to inhibit in its native form human T cell responses to several antigens. Here we show that gp 120 in soluble form also inhibits activation of a specific human T cell line that responds to gp120‐pulsed autologous antigen‐presenting cells. In addition the inhibitory property of gp120 for antigen‐driven T cell proliferation depends upon its ability to bind CD4 and is lost when CD4‐binding capacity is abolished by denaturation, or blocked by complexing with soluble CD4 or with polyclonal antibodies. In contrast, antigenicity of denatured or complexed gp120 for specific human T cells is preserved. Similar effects are also observed with another CD4‐binding reactant (i.e. anti‐Leu 3a MoAb), which stimulates and/ or inhibits human T cells specific for mouse immunoglobulins depending on native or denatured conformation.